NIH drops ACTIV-3 trial testing Lilly drug in hospitalized COVID-19 patients
Oct. 27, 2020
The ACTIV-3 phase III study testing Eli Lilly and Co.’s COVID-19 antibody candidate, LY-CoV555, which was paused two weeks ago following a participant’s unexplained illness, has now been halted, the company reported Oct. 26.